
Aaron P Mitchell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8923306/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-α. Journal of Clinical Investigation, 2009, 119, 3213-25.	3.9	226
2	Function and dynamics of PKD2 in <i>Chlamydomonas reinhardtii</i> flagella. Journal of Cell Biology, 2007, 179, 501-514.	2.3	183
3	Dendritic Cell Populations With Different Concentrations of Lipid Regulate Tolerance and Immunity in Mouse and Human Liver. Gastroenterology, 2012, 143, 1061-1072.	0.6	140
4	Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing?. Annals of Internal Medicine, 2021, 174, 353-361.	2.0	124
5	Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. JAMA Oncology, 2016, 2, 1628.	3.4	106
6	Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. Journal of Oncology Practice, 2015, 11, 491-497.	2.5	67
7	Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries. JAMA Internal Medicine, 2018, 178, 854.	2.6	44
8	Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology. Oncologist, 2019, 24, 632-639.	1.9	33
9	Statin cost effectiveness in primary prevention: A systematic review of the recent cost-effectiveness literature in the United States. BMC Research Notes, 2012, 5, 373.	0.6	31
10	Association Between Reimbursement Incentives and Physician Practice in Oncology. JAMA Oncology, 2019, 5, 893.	3.4	28
11	Deferred Systemic Therapy in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2015, 13, e159-e166.	0.9	17
12	Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. BMJ Evidence-Based Medicine, 2022, 27, 46-54.	1.7	16
13	Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics. Journal of Oncology Pharmacy Practice, 2018, 24, 424-432.	0.5	15
14	Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. Journal of the National Cancer Institute, 2022, 114, 419-426.	3.0	15
15	Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis. Trials, 2014, 15, 92.	0.7	12
16	Splenectomy as a Destination: Improving Quality of Care Among Asplenic Veterans Through a Travel Clinic. American Journal of Medicine, 2017, 130, 856-861.	0.6	9
17	Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1349-1353.	2.3	9
18	Isolation of intraflagellar transport trains. Cytoskeleton, 2013, 70, 439-452.	1.0	8

AARON P MITCHELL

#	Article	IF	CITATIONS
19	Use of High ost Cancer Treatments in Academic and Nonacademic Practice. Oncologist, 2020, 25, 46-54.	1.9	7
20	Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. Oncologist, 2021, 26, 771-778.	1.9	6
21	Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2023, 26, 126-132.	2.0	6
22	A Case of Highly Aggressive Extraskeletal Myxoid Chondrosarcoma. Case Reports in Oncology, 2011, 4, 377-384.	0.3	5
23	The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating. Pharmacoeconomics, 2020, 38, 737-745.	1.7	5
24	The Role of Physician Professional Networks in Physicians' Receipt of Pharmaceutical and Medical Device Industries' Payments. Journal of General Internal Medicine, 2021, 36, 1858-1866.	1.3	5
25	Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014–2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , 1-9.	2.3	5
26	Waldenström Macroglobulinemia in Hepatitis C: Case Report and Review of the Current Literature. Case Reports in Oncological Medicine, 2014, 2014, 1-7.	0.2	4
27	Trends in Female Representation on NCCN Guideline Panels. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1084-1086.	2.3	4
28	The Prescription Drug User Fee Act. Medical Care, 2022, Publish Ahead of Print, .	1.1	4
29	Use of Positron Emission Tomography Imaging: Another Nonbiological Source of Racial Disparities in US Cancer Care. Journal of the National Cancer Institute, 2020, 112, 1177-1178.	3.0	2
30	Association between Site-of-Care and the Cost and Modality of Radiotherapy for Prostate Cancer: Analysis of Medicare Beneficiaries from 2015 to 2017. Cancer Investigation, 2021, 39, 1-9.	0.6	1
31	We Should Treat Financial Toxicity With Curative, Rather Than Palliative, Intent. JCO Oncology Practice, 2021, , OP.21.00540.	1.4	1
32	Industry Payments to Rheumatologists Ought to Be Going Down, Not Up. Arthritis and Rheumatology, 2021, 73, 1951-1953.	2.9	1
33	The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis. Cancers, 2021, 13, 5977.	1.7	1
34	House Staff Perceptions of How Handoff Quality Influences Code Blue and Rapid Response Team Events. American Journal of Medical Quality, 2015, 30, 292-293.	0.2	0
35	Anti-EGFR and Anti-VEGF Agents in First-Line Therapy for Advanced Colorectal Cancer. Current Colorectal Cancer Reports, 2017, 13, 257-263.	1.0	0
36	Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1349-1353.	2.3	0